Alyssa Foster, Founder and CEODirective Strategy Group helps pharmaceutical and medical device companies avoid commercialization failure by addressing reimbursement early, teaching clients how the system works and building adaptable reimbursement pathways long before launch. By developing strategies that support coverage, payment and provider adoption, it helps clients prevent and overcome reimbursement barriers.
Leveraging deep industry expertise, its team combines strategic planning, reimbursement education and scenario-based decision-making to help clients navigate complex access challenges and support long-term adoption.
“We help companies understand why reimbursement systems work the way they do and how to navigate them strategically,” says Alyssa Foster, founder and CEO. “We also help them with the tactics needed to deploy their strategies.”
Designing the Foundation for Adoption
The U.S. healthcare reimbursement landscape involves multiple stakeholders, payment systems and coverage requirements that influence product adoption. For emerging innovators and international organizations, navigating this environment can be difficult.
Recognizing this challenge, Directive Strategy Group works with clients years before FDA approval to build strategies that support product success. Reimbursement strategies are developed based on how and where a product will be used. It evaluates the patient journey, clinical workflow and site of care to determine the most effective commercialization approach.
The process begins with assessing existing industry pathways to develop commercialization plans. Many innovative products, however, do not fit within existing reimbursement models.
In these cases, Directive Strategy Group develops multiple reimbursement scenarios, evaluates risks and outcomes and establishes contingency plans that set realistic expectations and adapt as regulatory, market and adoption conditions evolve.
In one instance, a manufacturer in the women’s health space aimed to overcome the market’s traditional self-pay fertility treatment model. The company helped establish a new reimbursement pathway by awarding a Current Procedural Terminology (CPT) code.
Working closely with the client’s sales teams and providers, it helped them navigate the highly specialized reimbursement landscape. It also supported broader efforts to expand insurance coverage for fertility treatments, creating pathways that could reduce financial barriers and improve patient access to care. It is now supporting the manufacturer in pull-through tactics to ensure appropriate CPT code utilization and reimbursement.
-
We help companies understand why reimbursement systems work the way they do and how to navigate them strategically.
Working closely with the client’s sales teams and providers, it helped them navigate the highly specialized reimbursement landscape. It also supported broader efforts to expand insurance coverage for fertility treatments, creating pathways that could reduce financial barriers and improve patient access to care. It is now supporting the manufacturer in pull-through tactics to ensure appropriate CPT code utilization and reimbursement.
Education as a Strategic Advantage
Training and education define Directive Strategy Group’s approach. The team incorporates education into every client engagement, ensuring clients understand what to do, why it matters and how reimbursement shapes commercialization outcomes.
Beyond advisory support, it offers formal training programs for C-suite executives, sales teams, field managers, hub teams and case management staff, tailoring each program to the reimbursement environment and compliance requirements.
It has also developed accessible, on-demand reimbursement education through digital platforms and partner websites. These resources simplify complex concepts into clear, visual and actionable learning experiences, helping professionals understand and apply strategies.
Building Growth through Partnership
Directive Strategy Group operates through a collaborative network of vendors and consulting partners across the healthcare ecosystem. These collaborations provide broader industry perspectives, allowing teams to share expertise, identify overlooked risks and opportunities and strengthen strategic decision-making. It believes shared expertise produces better solutions and client outcomes.
Each consultant contributes different experiences and insights, enabling Directive Strategy Group to solve complex reimbursement challenges through collective expertise. To stay ahead of evolving market dynamics, the team actively participates in cross-functional meetings and client discussions.
Its collaborative approach is reinforced through transparency, education and strong client relationships. By maintaining open communication and setting realistic expectations, it builds trust-based partnerships that drive repeat business and referrals.
As reimbursement systems evolve, Directive Strategy Group continues to help healthcare innovators transform reimbursement from a potential barrier into a strategic driver of commercialization success through planning, collaboration, education and adaptable commercialization pathways.
Choosing Healthcare Services that Strengthen Reimbursement Readiness
Healthcare services tied to reimbursement strategy now sit much closer to commercial success than many product teams once assumed. For pharmaceutical, medical device and diagnostic companies, clinical promise is not enough to carry a product into sustainable use. A therapy or procedure can clear regulatory review, show patient benefit and still face a weak launch if payers, providers and internal sales teams lack a clear path to reimbursement. The pressure is sharper for companies entering the U.S. market from systems where payment is more centralized or less dependent on a payer-by-payer strategy. The U.S. reimbursement environment rewards early planning, precise education and disciplined follow-through.
The strongest service partners help leadership teams confront reimbursement before launch pressure narrows their options. Early work should clarify how a product would be paid for if it entered the market today, what coding and coverage gaps remain and which actions should be taken before commercialization. That analysis must go beyond a static landscape review. It should help executives understand what not to pursue, where timing matters and how reimbursement choices affect sales readiness, provider adoption and patient access. Without that clarity, companies may invest in clinical, regulatory and manufacturing progress while leaving the payment path unresolved.
Effective healthcare reimbursement support also depends on matching the strategy to the actual use case. A product used in an inpatient setting may require a very different path from an office-administered drug, a supply-like device or a procedure that lacks a familiar payment route. Service partners must understand patient flow, site of care, coding routes, payer behavior and provider questions together. For emerging technologies, the work often cannot rely on precedent alone. It has to weigh possible pathways, prepare for setbacks and give management a practical way to shift course when timelines move, policy changes or adoption barriers appear.
Education has become equally important. Leadership teams, sales teams, field reimbursement managers and support teams need more than instructions. They need to understand why reimbursement questions arise, how to answer within compliance limits and when to escalate. Training should make complex concepts clear enough for commercial teams to use in live conversations without oversimplifying the risk. The same principle applies to patient and provider support. Not every company needs a large-volume hub model at launch. Some products require specialized, hands-on help until the access problem is understood, reduced or ready to transition to a larger service provider.
Directive Strategy Group stands out for companies that need reimbursement and market access guidance tied closely to commercialization. It supports pharmaceutical, medical device and diagnostic organizations from pre-commercial planning through the product or procedure lifecycle, with services spanning landscape assessment, strategy development, coding and payment applications, payer policy monitoring, support program planning, marketing resources and reimbursement training.
Its value is especially clear for teams that need candid pathway analysis, practical tactical planning and education that helps internal teams understand the reimbursement system they must work within. For executives choosing healthcare services in this field, Directive Strategy Group is a strong recommendation.
...Read more
Healthcare Services Info
Q1
What Do Healthcare Services Companies Help Healthcare Innovators Accomplish?
Healthcare Services Companies help organizations connect clinical progress with the operational, reimbursement and commercialization work needed for market adoption. Their role can include early pathway analysis, coding and payment planning, payer strategy, provider education and implementation support. When these elements are addressed before launch, product teams can identify barriers sooner, prepare realistic timelines and reduce the risk that an approved therapy, device or procedure enters the market without a workable route to payment.
Q2
How Does Directive Strategy Group Support Healthcare Commercialization?
Directive Strategy Group shows how Healthcare Services Companies can support commercialization through reimbursement planning. It works with pharmaceutical and medical device organizations years before FDA approval, examining the patient journey, clinical workflow and site of care to shape an appropriate pathway. It also develops multiple reimbursement scenarios, assesses risks and outcomes and prepares contingency plans. Its education-led model extends to executives, sales teams, field managers, hub teams and case management staff, helping each group understand both strategy and compliant execution.
Q3
Why Is Early Reimbursement Planning Important for New Healthcare Products?
Early reimbursement planning helps innovators understand how a product may be coded, covered and paid for before launch decisions become difficult to change. Healthcare Services Companies can reveal gaps between clinical value and practical adoption by studying payment pathways, provider requirements and likely payer questions. This gives leadership teams time to adjust evidence plans, commercial models, training and support programs while options remain open, rather than reacting after market entry.
Q4
What Capabilities Should Organizations Evaluate in a Healthcare Services Partner?
Organizations should look for structured analysis, practical implementation planning and the ability to explain complex systems clearly. Healthcare Services Companies should be able to connect reimbursement strategy with patient flow, site of care, coding routes, coverage conditions and provider adoption. Strong partners also test alternative scenarios, set realistic expectations and update plans as policy, regulatory or market conditions change. Clear communication matters because internal teams must understand not only what actions to take, but why those actions influence access.
Q5
How Can Reimbursement Education Improve Commercial Readiness?
Reimbursement education turns technical policy into guidance that commercial and support teams can use responsibly. Healthcare Services Companies may train leadership, sales, field reimbursement, hub and case management teams on common barriers, compliant communication and escalation points. Effective programs should match the product’s reimbursement environment and give participants enough context to handle real conversations without oversimplifying risk. On-demand learning can also reinforce knowledge across teams and support more consistent execution.
Q6
How Do Adaptable Strategies Support Long-Term Product Adoption?
Adaptable strategies prepare organizations for coding delays, policy changes, shifting payer expectations and unexpected adoption barriers. Healthcare Services Companies create value by building more than one possible route forward and defining when a team should change course. This approach supports continuity from pre-commercial planning through launch and later lifecycle decisions. It also helps organizations align reimbursement activity, provider support and internal education so that access efforts remain practical as market conditions evolve.
